Chengdu Kanghong Pharmaceutical Group Co., Ltd

Shenzhen Stock Exchange 002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd EBITDA for the year ending December 31, 2023: USD 195.59 M

Chengdu Kanghong Pharmaceutical Group Co., Ltd EBITDA is USD 195.59 M for the year ending December 31, 2023, a 23.32% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Chengdu Kanghong Pharmaceutical Group Co., Ltd EBITDA for the year ending December 31, 2022 was USD 158.61 M, a 84.62% change year over year.
Chengdu Kanghong Pharmaceutical Group Co., Ltd EBITDA for the year ending December 31, 2021 was USD 85.91 M, a 241.46% change year over year.
Chengdu Kanghong Pharmaceutical Group Co., Ltd EBITDA for the year ending December 31, 2020 was USD -60.73 M, a -145.37% change year over year.
Chengdu Kanghong Pharmaceutical Group Co., Ltd EBITDA for the year ending December 31, 2019 was USD 133.85 M, a 4.42% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shenzhen Stock Exchange: 002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd

CEO	Mr. Xiao Ke
IPO Date	June 29, 2015
Location	China
Headquarters	No.36, Shuxi Road
Employees	4,289
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.

Key trends

Past 5 years